FDA OKs Kevzara for moderate to severe rheumatoid arthritis
Sanofi and Regeneron Pharmaceuticals Inc. recently received approval from the Food & Drug Administration (FDA) for the drug Kevzara to treat people with moderate to severe rheumatoid arthritis.
Kevzara is for adults with rheumatoid arthritis who cannot tolerate disease-modifying antirheumatic drugs, which included methotrexate, according to a press release. Kevzara binds to the interleukin-6 receptor in the body and it has proven to get in the way of IL-6R mediated signaling, according to a press release. The IL-6 can contribute to the inflammation that comes with rheumatoid arthritis.
In rheumatoid arthritis, the immune system attacks joint tissues, with inflammation, pain and joint deterioration as symptoms of the disease. About 1.3 million Americans suffer from rheumatoid arthritis, and 75 percent are women, according to the release
The FDA approved Kevzara after seeing the results of trials of about 2,900 adults who had moderate to sever rheumatoid arthritis who did not react well to other medications. Over the course of two Phase 3 tests, Kevzara and disease-modifying antirheumatic drugs showed improvement in patients, the release stated.
Kevzara can either be used by itself or with methotrexate or other disease-modifying antirheumatic drugs.
Organizations in this story
Sanofi US 55 Corporate Dr Bridgewater, NJ - 08807